✦ LIBER ✦

113. Identification of Fabry disease-causing mutations that are responsive to the pharmacological chaperone AT1001

✍ Scribed by Xiaoyang Wu; Kirsten Mascioli; Evan Katz; Hui-Hwa Chang; Sang-Hoon Shin; Stefanie Kluepfel-Stahl; Gary Murray; Raphael Schiffmann; Kenneth Valenzano; David Lockhart; Elfrida Benjamin

Book ID: 116988298
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 55 KB
Volume: 93
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2007.10.125

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A double-blind, randomized, placebo-cont

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations

✍ Mathews Adera; Chemise Overton; Pol Boudes 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 73 KB

A randomized, open-label study to compar

A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT

✍ Mathews Adera; Allison Gladden; Pol Boudes 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB